Literature DB >> 10781211

A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers.

V Falanga1, M Sabolinski.   

Abstract

The efficacy of a bilayered, living skin construct (APLIGRAF(R) [Graftskin]) was evaluated in patients (n = 120) with hard- to-heal venous leg ulcers of greater than 1 year's duration. The study was prospective, randomized, and controlled. Patients received Graftskin plus compression therapy, or standard compression therapy (active control). Patients were evaluated for frequency and time to complete (100%) wound closure. Treatment with Graftskin was significantly more effective than active control in the percentage of patients healed by 6 months (47% vs. 19%; p < 0.005) and the median time to complete wound closure (p < 0.005). Analysis with multivariate regression methods, adjusting for factors generally thought to influence wound healing (duration, baseline area, depth, location, fibrinous wound bed, and infection), showed that patients treated with Graftskin were twice as likely to achieve complete wound closure by 6 months (p < 0.005), and over 60% more effective in achieving wound closure than active control (p < 0.01). These data indicate that Graftskin is an effective treatment for venous ulcers of greater than 1 year's duration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10781211     DOI: 10.1046/j.1524-475x.1999.00201.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  66 in total

Review 1.  Healing the diabetic wound and keeping it healed: modalities for the early 21st century.

Authors:  Matthew J Claxton; David G Armstrong; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

2.  [Possible interventions in impaired wound healing].

Authors:  S Coerper; S Beckert; H D Becker
Journal:  Chirurg       Date:  2004-05       Impact factor: 0.955

Review 3.  Regenerative medicine: Current therapies and future directions.

Authors:  Angelo S Mao; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 4.  Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration.

Authors:  Anthony D Metcalfe; Mark W J Ferguson
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

5.  Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience.

Authors:  Billy R Martin; Melinda Sangalang; Stephanie Wu; David G Armstrong
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

6.  Three-dimensional culture models of mammary gland.

Authors:  Jonathan J Campbell; Christine J Watson
Journal:  Organogenesis       Date:  2009-04       Impact factor: 2.500

Review 7.  Skin substitutes: an overview of the key players in wound management.

Authors:  Rajiv Nathoo; Nicole Howe; George Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2014-10

Review 8.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

9.  Wound-healing trajectories as outcome measures of venous stasis ulcer treatment.

Authors:  David L Steed; Donald P Hill; Matthew E Woodske; Wyatt G Payne; Martin C Robson
Journal:  Int Wound J       Date:  2006-03       Impact factor: 3.315

10.  Comparison of human umbilical cord blood-derived mesenchymal stem cells with healthy fibroblasts on wound-healing activity of diabetic fibroblasts.

Authors:  Jae-A Jung; Young-Don Yoon; Hyup-Woo Lee; So-Ra Kang; Seung-Kyu Han
Journal:  Int Wound J       Date:  2017-11-07       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.